DK1723144T3 - Yderligere heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamareceptor-antagonister - Google Patents

Yderligere heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamareceptor-antagonister

Info

Publication number: DK1723144T3
Authority: DK; Denmark
Prior art keywords: additional; receptor antagonists; glutamate receptor; metabotropic glutamate; compounds
Prior art date: 2004-02-18

Application number

DK05802855.6T

Other languages

English (en)

Inventor

Louise Edwards

Methvin Isaac

Martin Johansson

Annika Kers

Johan Malmberg

Donald Mcleod

Alexander Minidis

Karin Staaf

Abdelmalik Slassi

Tomislav Stefanac

Thomas Stormann

David Wensbo

Tao Xin

Jalaj Arora

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-18

Filing date

2005-02-15

Publication date

2011-01-03

2005-02-15 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2011-01-03 Application granted granted Critical

2011-01-03 Publication of DK1723144T3 publication Critical patent/DK1723144T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Physical Education & Sports Medicine (AREA)
Ophthalmology & Optometry (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Immunology (AREA)
Addiction (AREA)
Emergency Medicine (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DK05802855.6T 2004-02-18 2005-02-15 Yderligere heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamareceptor-antagonister DK1723144T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US60896004P	2004-02-18	2004-02-18
PCT/US2005/004774 WO2006014185A1 (en)	2004-02-18	2005-02-15	Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

Publications (1)

Publication Number	Publication Date
DK1723144T3 true DK1723144T3 (da)	2011-01-03

Family

ID=35447957

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK05802855.6T DK1723144T3 (da)	2004-02-18	2005-02-15	Yderligere heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamareceptor-antagonister

Country Status (27)

Country	Link
US (6)	US7585881B2 (da)
EP (2)	EP2311830A1 (da)
JP (1)	JP4912157B2 (da)
CN (2)	CN101096368A (da)
AT (1)	ATE483706T1 (da)
AU (1)	AU2005270208A1 (da)
BR (1)	BRPI0507497A (da)
CA (1)	CA2555566A1 (da)
CY (1)	CY1110965T1 (da)
DE (1)	DE602005023963D1 (da)
DK (1)	DK1723144T3 (da)
ES (1)	ES2352110T3 (da)
HK (1)	HK1099285A1 (da)
HR (1)	HRP20100654T1 (da)
IL (1)	IL177394A0 (da)
NO (1)	NO20063599L (da)
NZ (1)	NZ548954A (da)
PL (1)	PL1723144T3 (da)
PT (1)	PT1723144E (da)
RS (1)	RS51516B (da)
RU (1)	RU2370495C2 (da)
SG (1)	SG146657A1 (da)
SI (1)	SI1723144T1 (da)
UA (1)	UA84318C2 (da)
UY (1)	UY28766A1 (da)
WO (1)	WO2006014185A1 (da)
ZA (1)	ZA200606551B (da)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101723941A (zh) *	2002-08-09	2010-06-09	阿斯利康(瑞典)有限公司	作为代谢型谷氨酸受体-5调节剂的“1,2,4”二唑
US7585881B2 (en) *	2004-02-18	2009-09-08	Astrazeneca Ab	Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
JP2007533743A (ja) *	2004-04-20	2007-11-22	メルク　エンド　カムパニー　インコーポレーテッド	アルツハイマー病治療のためのβ−セクレターゼ阻害薬として有用な１，３，５−置換フェニル誘導体化合物
WO2006080533A1 (ja) *	2005-01-31	2006-08-03	Mochida Pharmaceutical Co., Ltd.	３－アミノ－１,２,４－トリアゾール誘導体
UY29796A1 (es) *	2005-09-29	2007-04-30	Astrazeneca Ab	Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
TW200811157A (en)	2006-05-05	2008-03-01	Astrazeneca Ab	mGluR5 modulators I
TW200808800A (en) *	2006-05-05	2008-02-16	Astrazeneca Ab	MGluR5 modulators V
TW200811179A (en) *	2006-05-05	2008-03-01	Astrazeneca Ab	mGluR5 modulators VI
US7935715B2 (en) *	2006-07-28	2011-05-03	Boehringer Ingelheim International Gmbh	Compounds which modulate the CB2 receptor
TW200821305A (en) *	2006-10-05	2008-05-16	Astrazeneca Ab	MGluR5 modulators
EP2167464B1 (en) *	2007-05-25	2014-12-03	AbbVie Deutschland GmbH & Co KG	Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
EP2181110A2 (en) *	2007-07-13	2010-05-05	ADDEX Pharma S.A.	Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
US7960422B2 (en) *	2007-10-19	2011-06-14	Astrazeneca Ab	Pharmaceutically active compounds containing tetrazolyl and triazolyl rings
WO2009054786A1 (en) *	2007-10-26	2009-04-30	Astrazeneca Ab	1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5
WO2009054785A1 (en) *	2007-10-26	2009-04-30	Astrazeneca Ab	1,2,4-triazole ether derivatives as modulators of mglur5
WO2009061652A1 (en) *	2007-11-07	2009-05-14	Boehringer Ingelheim International Gmbh	Compounds which modulate the cb2 receptor
MX2010009732A (es) *	2008-03-03	2010-09-30	Stiefel Laboratories	Procedimientos para preparar compuestos de diol y dioxolano enantiomericamente puros.
EA021672B1 (ru)	2008-05-14	2015-08-31	Дзе Скриппс Рисёч Инститьют	Модуляторы рецепторов сфингозин-1-фосфата и их применение
EP2326629B1 (en) *	2008-07-10	2013-10-02	Boehringer Ingelheim International GmbH	Sulfone compounds which modulate the cb2 receptor
AU2009282522A1 (en) *	2008-08-12	2010-02-18	Astrazeneca Ab	A new crystalline form of 4- (5- { (IR) -1- [5- (3- chlorophenyl) isoxazol-3-yl] ethoxy } -4-methyl-4H-l, 2, 4- triazol-3-yl) pyridine
MX2011001549A (es) *	2008-08-12	2011-03-15	Astrazeneca Ab	Forma cristalina de 4-(5-{(1r)-1-[5-(3-clorofenil)isoxazol-3-il]et oxi}-4-metil-4h-1,2,4-triazol-3-il)piridina.
MX2011002904A (es)	2008-09-25	2011-04-11	Boehringer Ingelheim Int	Compuestos de sulfonilo que modulan selectivamente el receptor de cb2.
CN102256967A (zh) *	2008-12-18	2011-11-23	阿斯利康(瑞典)有限公司	制备3-{4-甲基-5-[(1r)-1-(2-(3-甲基苯基-2h-四唑-5-基)-乙氧基]-4h-[1,2,4]三唑-3-基}-吡啶、4-甲基-3-甲基硫基-5-(吡啶-3-基)-1,2,4-三唑和(1r)-1-[2-(3-甲基苯基)-2h-四唑-5-基]乙醇的方法
US8349852B2 (en)	2009-01-13	2013-01-08	Novartis Ag	Quinazolinone derivatives useful as vanilloid antagonists
US8889670B2 (en)	2009-02-18	2014-11-18	Boehringer Ingelheim International Gmbh	Heterocyclic compounds which modulate the CB2 receptor
US20120029190A1 (en) *	2009-04-03	2012-02-02	Douglas Burdi	Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
US20100273805A1 (en) *	2009-04-23	2010-10-28	Astrazeneca Ab	Sulphide bridged derivatives as modulators of mglur5 733
WO2010139966A1 (en) *	2009-06-05	2010-12-09	Oslo University Hospital Hf	Azole derivatives as wtn pathway inhibitors
US8299103B2 (en)	2009-06-15	2012-10-30	Boehringer Ingelheim International Gmbh	Compounds which selectively modulate the CB2 receptor
JP5756800B2 (ja)	2009-06-16	2015-07-29	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体
US8383651B2 (en) *	2009-09-22	2013-02-26	Boehringer Ingelheim International Gmbh	Compounds which selectively modulate the CB2 receptor
CN102724880B (zh) *	2009-11-13	2016-09-14	瑞塞普托斯有限责任公司	1-磷酸鞘氨醇受体调节剂及手性合成方法
EA025672B1 (ru) *	2009-11-13	2017-01-30	Рецептос Ллк	Селективные гетероциклические модуляторы рецептора сфингозин-1-фосфата
JP5650233B2 (ja)	2009-11-13	2015-01-07	レセプトスインコーポレイテッドＲｅｃｅｐｔｏｓ，Ｉｎｃ．	選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
CA2784768C (en)	2009-12-29	2015-02-03	Eli Lilly And Company	Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia
CN101712641B (zh) *	2009-12-29	2013-05-08	江苏工业学院	一种甲硫基苯甲酸的制备方法
EP2523936A1 (en)	2010-01-15	2012-11-21	Boehringer Ingelheim International GmbH	Compounds which modulate the cb2 receptor
WO2011092290A1 (en)	2010-02-01	2011-08-04	Novartis Ag	Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es)	2010-02-01	2012-03-07	Novartis Ag	Derivados de ciclohexil-amida como antagonistas de los receptores de crf
WO2011095450A1 (en)	2010-02-02	2011-08-11	Novartis Ag	Cyclohexyl amide derivatives as crf receptor antagonists
WO2011109324A1 (en)	2010-03-05	2011-09-09	Boehringer Ingelheim International Gmbh	Tetrazole compounds which selectively modulate the cb2 receptor
AR081626A1 (es)	2010-04-23	2012-10-10	Cytokinetics Inc	Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es)	2010-04-23	2012-08-08	Cytokinetics Inc	Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
WO2011133920A1 (en)	2010-04-23	2011-10-27	Cytokinetics, Inc.	Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
JP5746764B2 (ja)	2010-07-22	2015-07-08	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｂ２受容体を調節する化合物
EP2632900A2 (en) *	2010-10-28	2013-09-04	Merck Sharp & Dohme Corp.	Caprolactam mglur5 receptor modulators
CA2820800A1 (en)	2010-12-08	2012-06-14	Oslo University Hospital Hf	Triazole derivatives as wnt signaling pathway inhibitors
DE102010063974B4 (de) *	2010-12-22	2021-10-07	Thomas Rühl	Pharmakologische Wirkstoffe und Radiodiagnostika mit 18F-markierter 3-Aryl- oder 3-Heteroaryl-1,2,4-oxadiazoleinheit und Verfahren zu deren Herstellung
JP6031458B2 (ja)	2011-03-18	2016-11-24	ノバルティスアーゲー	パーキンソン病におけるドーパミン誘発ジスキネジアに使用するためのアルファ７ニコチン性アセチルコリン受容体アクティベーターとｍＧｌｕＲ５アンタゴニストの組み合わせ剤
US8759380B2 (en) *	2011-04-22	2014-06-24	Cytokinetics, Inc.	Certain heterocycles, compositions thereof, and methods for their use
EP2706999B1 (en)	2011-05-13	2019-08-28	Celgene International II Sàrl	Selective heterocyclic sphingosine 1 phosphate receptor modulators
EP2545964A1 (en)	2011-07-13	2013-01-16	Phenex Pharmaceuticals AG	Novel FXR (NR1H4) binding and activity modulating compounds
US9199975B2 (en)	2011-09-30	2015-12-01	Asana Biosciences, Llc	Biaryl imidazole derivatives for regulating CYP17
EP2803668A1 (en)	2013-05-17	2014-11-19	Boehringer Ingelheim International Gmbh	Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
SI3363790T1 (sl)	2013-09-06	2020-08-31	Aurigene Discovery Technologies Limited	1,2,4-oksadiazolni derivati kot imunomodulatorji
WO2016139164A1 (en) *	2015-03-05	2016-09-09	Bayer Cropscience Aktiengesellschaft	Process for preparing substituted phenylisoxazoline derivatives
JP6815686B2 (ja)	2015-03-10	2021-01-20	オーリジーンディスカバリーテクノロジーズリミテッドＡｕｒｉｇｅｎｅＤｉｓｃｏｖｅｒｙＴｅｃｈｎｏｌｏｇｉｅｓＬｉｍｉｔｅｄ	免疫調節剤としての１，２，４−オキサジアゾールおよびチアジアゾール化合物
CU20170118A7 (es) *	2015-03-10	2018-02-08	Aurigene Discovery Tech Ltd	Compuestos de tiadiazol y 1,2,4-oxadiazol 3-sustituidos como inmunomoduladores
CA2968836A1 (en)	2016-06-13	2017-12-13	Gilead Sciences, Inc.	Fxr (nr1h4) modulating compounds
ES2921432T3 (es)	2016-06-13	2022-08-25	Gilead Sciences Inc	Derivados de azetidina como moduladores de FXR (NR1H4)
EP3600309B1 (en)	2017-03-28	2022-06-22	Gilead Sciences, Inc.	Therapeutic combinations for treating liver diseases
WO2019061324A1 (en)	2017-09-29	2019-04-04	Curis Inc.	CRYSTALLINE FORMS OF IMMUNOMODULATORS
JP2020536863A (ja)	2017-10-06	2020-12-17	フォーマセラピューティクス，インコーポレイテッド	ユビキチン特異的ペプチダーゼ３０の阻害
BR112020006669A2 (pt)	2017-10-11	2020-09-24	Aurigene Discovery Technologies Limited	formas cristalinas de 1,2,4-oxadiazol 3-substituído
WO2019087087A1 (en)	2017-11-03	2019-05-09	Aurigene Discovery Technologies Limited	Dual inhibitors of tim-3 and pd-1 pathways
KR20200084333A (ko)	2017-11-06	2020-07-10	오리진 디스커버리 테크놀로지스 리미티드	면역조절을 위한 병행 요법
AU2018367939B2 (en) *	2017-11-16	2023-07-13	Montdorex Inc.	Mono- and di-amidine endo-exonuclease inhibitors and methods for inhibiting endo-exonuclease activity
MX2020012180A (es)	2018-05-17	2021-01-29	Forma Therapeutics Inc	Compuestos biciclicos fusionados utiles como inhibidores de la peptidasa 30 especifica de ubiquitina.
CN113166108A (zh)	2018-10-05	2021-07-23	福马治疗有限公司	作为泛素特异性蛋白酶30(usp30)抑制剂的稠合吡咯啉
CA3124702A1 (en)	2019-01-15	2020-07-23	Gilead Sciences, Inc.	Fxr (nr1h4) modulating compounds
CN118388473A (zh)	2019-02-19	2024-07-26	吉利德科学公司	Fxr激动剂的固体形式
AU2020267356A1 (en) *	2019-05-03	2022-01-06	Praxis Precision Medicines, Inc.	KCNT1 inhibitors and methods of use
MX2022008395A (es) *	2020-01-07	2022-09-26	Disarm Therapeutics Inc	Inhibidores de sarm1.
TW202334117A (zh)	2020-08-24	2023-09-01	美商達薩瑪治療公司	Ｓａｒｍ１之抑制劑
WO2022231872A1 (en) *	2021-04-29	2022-11-03	Praxis Precision Medicines, Inc.	Kcnt1 inhibitors and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4538833A (en) *	1983-12-08	1985-09-03	P I E International Inc.	Publication
US5403138A (en) *	1991-10-09	1995-04-04	Fuji Photo Film Co., Ltd.	Booklet album including a double-sided photograph and a method of making the same
US5332265A (en) *	1993-01-22	1994-07-26	Minnesota Mining And Manufacturing Company	Advertising assembly
IL148157A0 (en)	1999-08-19	2002-09-12	Nps Pharma Inc	Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2003053922A2 (en)	2001-12-19	2003-07-03	Merck & Co., Inc.	Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
BR0313266A (pt)	2002-08-09	2005-06-21	Astrazeneca Ab	Compostos, respectivos processos de preparação e uso, formulação farmacêutica e métodos de prevenção e/ou tratamento de um distúrbio mediado pelo receptor de mglur5 e de inibição da ativação de receptores de mglur5
AU2003264018A1 (en) *	2002-08-09	2004-02-25	Astrazeneca Ab	Compounds having an activity at metabotropic glutamate receptors
CN101723941A (zh) *	2002-08-09	2010-06-09	阿斯利康(瑞典)有限公司	作为代谢型谷氨酸受体-5调节剂的“1,2,4”二唑
US7585881B2 (en) *	2004-02-18	2009-09-08	Astrazeneca Ab	Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
UY29796A1 (es) *	2005-09-29	2007-04-30	Astrazeneca Ab	Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor

2005
- 2005-02-09 US US11/053,752 patent/US7585881B2/en not_active Expired - Fee Related
- 2005-02-15 UA UAA200608867A patent/UA84318C2/ru unknown
- 2005-02-15 WO PCT/US2005/004774 patent/WO2006014185A1/en active Application Filing
- 2005-02-15 US US10/588,702 patent/US20070179188A1/en not_active Abandoned
- 2005-02-15 AU AU2005270208A patent/AU2005270208A1/en not_active Abandoned
- 2005-02-15 SI SI200531175T patent/SI1723144T1/sl unknown
- 2005-02-15 ES ES05802855T patent/ES2352110T3/es active Active
- 2005-02-15 JP JP2006554165A patent/JP4912157B2/ja not_active Expired - Fee Related
- 2005-02-15 RU RU2006128446/04A patent/RU2370495C2/ru not_active IP Right Cessation
- 2005-02-15 DE DE602005023963T patent/DE602005023963D1/de active Active
- 2005-02-15 CA CA002555566A patent/CA2555566A1/en not_active Abandoned
- 2005-02-15 EP EP10182161A patent/EP2311830A1/en not_active Withdrawn
- 2005-02-15 BR BRPI0507497-5A patent/BRPI0507497A/pt not_active IP Right Cessation
- 2005-02-15 PT PT05802855T patent/PT1723144E/pt unknown
- 2005-02-15 SG SG200806914-8A patent/SG146657A1/en unknown
- 2005-02-15 CN CNA2007101278476A patent/CN101096368A/zh active Pending
- 2005-02-15 RS RSP-2010/0525A patent/RS51516B/en unknown
- 2005-02-15 CN CNA2005800043063A patent/CN1984907A/zh active Pending
- 2005-02-15 DK DK05802855.6T patent/DK1723144T3/da active
- 2005-02-15 PL PL05802855T patent/PL1723144T3/pl unknown
- 2005-02-15 NZ NZ548954A patent/NZ548954A/xx unknown
- 2005-02-15 EP EP05802855A patent/EP1723144B1/en active Active
- 2005-02-15 AT AT05802855T patent/ATE483706T1/de active
- 2005-02-18 UY UY28766A patent/UY28766A1/es not_active Application Discontinuation
2006
- 2006-08-07 ZA ZA200606551A patent/ZA200606551B/en unknown
- 2006-08-08 NO NO20063599A patent/NO20063599L/no not_active Application Discontinuation
- 2006-08-09 IL IL177394A patent/IL177394A0/en unknown
2007
- 2007-05-22 HK HK07105399.9A patent/HK1099285A1/xx not_active IP Right Cessation
- 2007-08-18 US US11/840,953 patent/US20080045571A1/en not_active Abandoned
- 2007-08-18 US US11/840,954 patent/US20070293545A1/en not_active Abandoned
- 2007-08-18 US US11/840,952 patent/US20080015234A1/en not_active Abandoned
- 2007-08-18 US US11/840,955 patent/US20080015204A1/en not_active Abandoned
2010
- 2010-11-29 HR HR20100654T patent/HRP20100654T1/hr unknown
- 2010-12-03 CY CY20101101116T patent/CY1110965T1/el unknown

Also Published As

Publication number	Publication date
ATE483706T1 (de)	2010-10-15
PL1723144T3 (pl)	2011-02-28
JP4912157B2 (ja)	2012-04-11
ZA200606551B (en)	2007-11-28
NZ548954A (en)	2009-07-31
EP2311830A1 (en)	2011-04-20
SI1723144T1 (sl)	2011-01-31
RS51516B (en)	2011-06-30
EP1723144A1 (en)	2006-11-22
HK1099285A1 (en)	2007-08-10
CA2555566A1 (en)	2006-02-09
CN101096368A (zh)	2008-01-02
US20080015204A1 (en)	2008-01-17
US20050272779A1 (en)	2005-12-08
PT1723144E (pt)	2010-12-07
JP2007523168A (ja)	2007-08-16
SG146657A1 (en)	2008-10-30
WO2006014185A1 (en)	2006-02-09
NO20063599L (no)	2006-10-27
US20080045571A1 (en)	2008-02-21
ES2352110T3 (es)	2011-02-15
UA84318C2 (ru)	2008-10-10
US20080015234A1 (en)	2008-01-17
US20070179188A1 (en)	2007-08-02
BRPI0507497A (pt)	2007-07-10
IL177394A0 (en)	2006-12-10
US7585881B2 (en)	2009-09-08
US20070293545A1 (en)	2007-12-20
CN1984907A (zh)	2007-06-20
DE602005023963D1 (de)	2010-11-18
RU2370495C2 (ru)	2009-10-20
UY28766A1 (es)	2005-08-31
RU2006128446A (ru)	2008-03-27
AU2005270208A1 (en)	2006-02-09
EP1723144B1 (en)	2010-10-06
HRP20100654T1 (hr)	2011-01-31
CY1110965T1 (el)	2015-06-11

Publication	Publication Date	Title
DK1723144T3 (da)	2011-01-03	Yderligere heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamareceptor-antagonister
NO20033711D0 (no)	2003-08-20	Heteropolysykliske forbindelser og deres anvendelse som metabotrope glutamatatreseptorantagonister
NO20062677L (no)	2006-08-09	Benzyleteraminforbindelser anvendbare som CCR-5-antagonister
MX2008001606A (es)	2008-04-14	Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
HK1101178A1 (en)	2007-10-12	Alkynyl derivatives as modulators of metabotropic glutamate receptors
IL196543A (en)	2013-09-30	Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
NO20070224L (no)	2007-04-02	2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
MX2007014405A (es)	2008-04-21	Novedosos derivados de oxadiazol y su uso como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.
DE602006006712D1 (de)	2009-06-18	Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
GB0504828D0 (en)	2005-04-13	Therapeutic agents
ATE467632T1 (de)	2010-05-15	Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
SE0301446D0 (sv)	2003-05-16	New Compounds
ATE449776T1 (de)	2009-12-15	Pyrroloä2,3-cüpyridinderivate
HK1116477A1 (en)	2008-12-24	Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders
GT200500309A (es)	2006-09-11	Derivados de sulfonilbencilimidazol
BRPI0417858A (pt)	2007-04-27	composto, composição farmacêutica, e, uso de uma composição farmacêutica
NO20082214L (no)	2008-07-31	1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
CR10255A (es)	2008-11-26	"nuevas composiciones terapéuticas para el tratamiento o la prevención de trastornos psicóticos"
MX2008001608A (es)	2008-04-14	Piperazinas acetilenicas como antagonistas de receptor de glutamato metabotropico.
EA200701181A1 (ru)	2008-02-28	Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
MX2008001607A (es)	2008-04-14	Piperazinas biciclicas como antagonistas del receptor de glutamato metabotropico.
PA8545601A1 (es)	2003-01-24	Derivados de 4-aminopirimidina
MY148488A (en)	2013-04-30	Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
SE0403118D0 (sv)	2004-12-21	New compounds 2
NO20081529L (no)	2008-06-18	Naftyridinderivater